MIT-3301

MIT-3301 is a preclinical-stage trivalent, trispecific single-domain antibody (sdAb) construct designed as a universal reversal agent for direct oral anticoagulants (DOACs) that inhibit factor Xa, specifically apixaban, edoxaban, and rivaroxaban. Developed by Mithridate in close collaboration with the Synapse Research Institute, MIT-3301 consists of three distinct high-affinity single-domain antibody monomers joined by peptide linkers, each targeting one of the three DOACs. Unlike other reversal agents such as andexanet alfa, which target factor Xa and can disrupt natural anticoagulant pathways (potentially leading to prothrombotic complications), MIT-3301 directly binds and neutralizes the circulating DOAC molecules themselves without interfering with the host's coagulation system. Preclinical studies have demonstrated that MIT-3301 effectively reverses DOAC-induced anticoagulation and reduces bleeding in traumatic models without inducing procoagulant biases.

Other names

tri-head sdAb constructtrivalent single-domain antibody constructtrivalent trispecific single domain antibody